Literature DB >> 18306167

Dysferlin-deficient muscular dystrophy features amyloidosis.

Simone Spuler1, Miriam Carl, Joanna Zabojszcza, Volker Straub, Kate Bushby, Steven A Moore, Sylvia Bähring, Katrin Wenzel, Uwe Vinkemeier, Christoph Rocken.   

Abstract

OBJECTIVE: Dysferlin (DYSF) gene mutations cause limb girdle muscular dystrophy type 2B and Miyoshi's myopathy. The consequences of DYSF mutations on protein structure are poorly understood.
METHODS: The gene encoding dysferlin was sequenced in patients with suspected dysferlin-deficient muscular dystrophy. Muscle biopsy specimens were analyzed by histochemistry, immunohistochemistry, and electron microscopy. Antibodies against N-terminal dysferlin-peptides were raised.
RESULTS: We found three families with muscular dystrophy caused by homozygous or compound heterozygous DYSF mutations featuring sarcolemmal and interstitial amyloid deposits. These mutations were all located in the N-terminal region of the protein. Dysferlin was a constituent of the amyloid deposits.
INTERPRETATION: Limb girdle muscular dystrophy type 2B is the first muscular dystrophy associated with amyloidosis. Molecular treatment strategies will necessarily have to consider the presence of amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306167     DOI: 10.1002/ana.21309

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  [Update on immunohistological classification of amyloidoses].

Authors:  C Röcken
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

2.  Novel diagnostic features of dysferlinopathies.

Authors:  Xiomara Q Rosales; Julie M Gastier-Foster; Sarah Lewis; Malik Vinod; Devon L Thrush; Caroline Astbury; Robert Pyatt; Shalini Reshmi; Zarife Sahenk; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

Review 3.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

4.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

5.  Diagnostic muscle biopsies in the era of genetics: the added value of myopathology in a selection of limb-girdle muscular dystrophy patients.

Authors:  Boel De Paepe; Elise Velghe; Linnea Salminen; Balint Toth; Pieter Olivier; Jan L De Bleecker
Journal:  Acta Neurol Belg       Date:  2021-01-05       Impact factor: 2.396

6.  Equal force recovery in dysferlin-deficient and wild-type muscles following saponin exposure.

Authors:  Piming Zhao; Li Xu; Younss Ait-Mou; Pieter P de Tombe; Renzhi Han
Journal:  J Biomed Biotechnol       Date:  2011-09-18

7.  Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.

Authors:  Eduard Gallardo; Noemi de Luna; Jordi Diaz-Manera; Ricardo Rojas-García; Lidia Gonzalez-Quereda; Bàrbara Flix; Antoine de Morrée; Silvère van der Maarel; Isabel Illa
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

8.  Ahnak1 abnormally localizes in muscular dystrophies and contributes to muscle vesicle release.

Authors:  Ute Zacharias; Bettina Purfürst; Verena Schöwel; Ingo Morano; Simone Spuler; Hannelore Haase
Journal:  J Muscle Res Cell Motil       Date:  2011-11-05       Impact factor: 2.698

9.  Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy.

Authors:  Susanne Philippi; Anne Bigot; Andreas Marg; Vincent Mouly; Simone Spuler; Ute Zacharias
Journal:  PLoS Curr       Date:  2012-02-02

10.  Dysferlin-peptides reallocate mutated dysferlin thereby restoring function.

Authors:  Verena Schoewel; Andreas Marg; Severine Kunz; Tim Overkamp; Romy Siegert Carrazedo; Ute Zacharias; Peter T Daniel; Simone Spuler
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.